Zhejiang Starry Pharmaceutical Co.,Ltd. Stock price

Equities

603520

CNE1000026N8

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
11.93 CNY -2.53% Intraday chart for Zhejiang Starry Pharmaceutical Co.,Ltd. -8.30% -15.27%
Sales 2023 * 2.44B 337M Sales 2024 * 2.97B 411M Capitalization 4.09B 565M
Net income 2023 * 120M 16.6M Net income 2024 * 290M 40.12M EV / Sales 2023 * 1.68 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.38 x
P/E ratio 2023 *
34.1 x
P/E ratio 2024 *
14.1 x
Employees 1,842
Yield 2023 *
0.96%
Yield 2024 *
2.1%
Free-Float 62.03%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hu Jinsheng agreed to acquire 36% stake in Xianju Juhe Financial Services Co., Ltd. from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 19.8 million. CI
Shanghai Ddsome Laboratories Co., Ltd announced that it has received funding from Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co.,Ltd. CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shanghai Ddsome Laboratories Co., Ltd announced that it expects to receive CNY 28 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd. CI
Starry Pharma’s Generic X-Ray Contrast Agent Gets Marketing Approval MT
Zhejiang Starry Pharma’s CFO Resigns MT
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership. CI
Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 2.05 billion in funding CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day-2.53%
1 week-8.30%
Current month+15.38%
1 month+8.65%
3 months-12.86%
6 months-23.62%
Current year-15.27%
More quotes
1 week
11.93
Extreme 11.93
12.77
1 month
9.89
Extreme 9.89
13.62
Current year
7.86
Extreme 7.86
14.30
1 year
7.86
Extreme 7.86
19.25
3 years
7.86
Extreme 7.86
57.26
5 years
7.86
Extreme 7.86
70.36
10 years
6.13
Extreme 6.1334
70.36
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 09-08-31
Director of Finance/CFO 39 22-12-25
Chairman 45 10-12-31
Members of the board TitleAgeSince
Director/Board Member 45 23-05-08
Director/Board Member 61 23-05-08
Director/Board Member 69 03-12-31
More insiders
Date Price Change Volume
24-03-27 11.93 -2.53% 4,985,500
24-03-26 12.24 +1.58% 5,858,644
24-03-25 12.05 -2.35% 4,728,260
24-03-22 12.34 -2.99% 6,420,140
24-03-21 12.72 -2.23% 8,989,339

End-of-day quote Shanghai S.E., March 26, 2024

More quotes
Zhejiang Starry Pharmaceutical Co., Ltd. is principally engaged in the research and development (R&D), production and sales of X-ray contrast medium, quinolone antimicrobial agents and other drugs' pharmaceutical raw materials and intermediates. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.93 CNY
Average target price
19.87 CNY
Spread / Average Target
+66.55%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Zhejiang Starry Pharmaceutical Co.,Ltd. - Shanghai S.E.